Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.1.1.63 - methylated-DNA-[protein]-cysteine S-methyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
DNA-binding mechanism of the Escherichia coli Ada O(6)-alkylguanine-DNA alkyltransferase.
Adenocarcinoma
In vitro evaluation of temozolomide combined with X-irradiation.
Low frequency of promoter methylation of O6-methylguanine DNA methyltransferase and hMLH1 in ulcerative colitis-associated tumors: comparison with sporadic colonic tumors.
Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma.
O6-methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Rectal Adenocarcinoma After Chemoradiotherapy Treatment: Clinical Implications
Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach.
Regulation of O6-methylguanine-DNA methyltransferase by methionine in human tumour cells.
The prognostic impact of O6-Methylguanine-DNA Methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma.
Adenocarcinoma of Lung
Inactivation of O6-methylguanine-DNA methyltransferase in human lung adenocarcinoma relates to high-grade histology and worse prognosis among smokers.
Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression.
Adenoma
Analysis of K-ras codon 12 mutation in flat and nodular variants of serrated adenoma in the colon.
Human colorectal mucosal O6-alkylguanine DNA-alkyltransferase activity and DNA-N7-methylguanine levels in colorectal adenoma cases and matched referents.
Low frequency of promoter methylation of O6-methylguanine DNA methyltransferase and hMLH1 in ulcerative colitis-associated tumors: comparison with sporadic colonic tumors.
Molecular markers of carcinogenesis for risk stratification of individuals with colorectal polyps: a case-control study.
Reduced lung tumorigenesis in human methylguanine DNA--methyltransferase transgenic mice achieved by expression of transgene within the target cell.
Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients.
Adenomatous Polyposis Coli
Alteration of O6-methylguanine-DNA methyltransferase in colorectal neoplasms in sporadic and familial adenomatous polyposis patients.
DNA methylation profiles of lung tumors.
Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
Immunohistochemical and molecular features of sporadic and FAP-associated duodenal adenomas of the ampullary and nonampullary mucosa.
Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea.
[Aberrant promoter methylation of tumor suppressor genes in serum from lung cancer patients: frequency and correlation with clinicopathological characteristics]
Alzheimer Disease
O6-methylguanine-DNA methyltransferase activities from exponentially growing human T lymphocytes: similar activities in controls and Alzheimer's disease patients.
O6-methylguanine-DNA methyltransferase in lymphocytes of the elderly with and without Alzheimer's disease.
Anemia
Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity.
Arthritis, Rheumatoid
Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States.
Astrocytoma
A comparative immunohistochemistry of O6-methylguanine-DNA methyltransferase and p53 in diffusely infiltrating astrocytomas.
Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression.
Evaluation of O6-methylguanine-DNA methyltransferase enzyme expression effect on survival of patients with Grade 4 brain astrocytoma.
Genetic pathways to glioblastomas.
Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas.
Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas.
O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course.
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma.
Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas.
Ataxia Telangiectasia
Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells.
Triptolide induced DNA damage in A375.S2 human malignant melanoma cells is mediated via reduction of DNA repair genes.
Blister
Enzymatic repair of premutagenic DNA lesions in human epidermis. Quantitation of O6-methylguanine-DNA methyltransferase and uracil-DNA glycosylase activities.
Bloom Syndrome
O6-methylguanine methyltransferase increases before S phase in normal human cells but does not increase in hypermutable Bloom's syndrome cells.
Brain Neoplasms
A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase.
Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
An overview of neuro-oncology research and practice in Iran, three years with the NOSC initiative.
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.
Comparison of O6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain.
Contribution of O6-methylguanine-DNA methyltransferase to monofunctional alkylating-agent resistance in human brain tumor-derived cell lines.
Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines.
Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage.
DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors.
DNA repair protein O6-alkylguanine-DNA alkyltransferase is phosphorylated by two distinct and novel protein kinases in human brain tumour cells.
Expression of O6-methylguanine-DNA methyltransferase and chloroethylnitrosourea resistance of human brain tumors.
Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression.
Influence of O6-methylguanine-DNA methyltransferase activity on chloroethylnitrosourea chemotherapy in brain tumors.
Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy.
Lack of expression of tumor-suppressor genes in human malignant glioma cell lines.
Lack of the DNA repair protein O6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors.
Linkage between O6-methylguanine-DNA methyltransferase (O6-MT) activity and cellular resistance to antitumour nitrosoureas in cultured rat brain tumour cell strains.
O6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors.
O6-alkylguanine-DNA alkyltransferase activity in human brain tumors.
O6-methylguanine-DNA methyltransferase activity in breast and brain tumors.
O6-methylguanine-DNA methyltransferase in human brain tumors detected by activity assay and monoclonal antibodies.
O6-Methylguanine-DNA methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics.
O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors.
O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy.
p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors.
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Phosphorylation of O6-alkylguanine-DNA alkyltransferase: experience with a GST-fusion protein and a new pull-down assay.
Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
Promoter methylation status of multiple genes in brain metastases of solid tumors.
Protein phosphorylation is a regulatory mechanism for O6-alkylguanine-DNA alkyltransferase in human brain tumor cells.
Quantification of O6-methylguanine-DNA methyltransferase mRNA in human brain tumors.
Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts.
Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents.
Residual Deep Convolutional Neural Network Predicts MGMT Methylation Status.
Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.
Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.
The effect of race on the prognosis of the glioblastoma patient: a brief review.
The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells.
Transcriptional Pausing and Activation at Exons-1 and -2, Respectively, Mediate the MGMT Gene Expression in Human Glioblastoma Cells.
[Interdisciplinary neuro-oncology: part 1: diagnostics and operative therapy of primary brain tumors].
[Interdisciplinary neuro-oncology: part 2: systemic therapy of primary brain tumors].
Breast Neoplasms
Association Between MGMT Promoter Methylation and Breast Cancer: a Meta-Analysis.
Bisdemethoxycurcumin induces DNA damage and inhibits DNA repair associated protein expressions in NCI-H460 human lung cancer cells.
Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics.
Bufalin induces cell death in human lung cancer cells through disruption of DNA damage response pathways.
Combined depletion of O6-alkylguanine-DNA alkyltransferase and glutathione to modulate nitrosourea resistance in breast cancer.
Curcumin causes DNA damage and affects associated protein expression in HeLa human cervical cancer cells.
Curcumin Triggers DNA Damage and Inhibits Expression of DNA Repair Proteins in Human Lung Cancer Cells.
Demethoxycurcumin-induced DNA Damage Decreases DNA Repair-associated Protein Expression Levels in NCI-H460 Human Lung Cancer Cells.
DNA Methylation in Human Breast Cancer Cell Lines Adapted to High Nitric Oxide.
Epigenetic deregulation of DNA repair and its potential for therapy.
Expression of the O6-alkylguanine-DNA alkyltransferase gene is elevated in human breast tumor cells.
Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours.
Immunohistochemical Analysis of DNA Repair- and Drug-Efflux-Associated Molecules in Tumor and Peritumor Areas of Glioblastoma.
Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells.
MGMT inhibition in ER positive breast cancer leads to CDC2, TOP2A, AURKB, CDC20, KIF20A, Cyclin A2, Cyclin B2, Cyclin D1, ER? and Survivin inhibition and enhances response to temozolomide.
Polymorphisms in O6-methylguanine DNA methyltransferase and breast cancer risk.
Synthesis and preliminary biological evaluation of radiolabeled O6-benzylguanine derivatives, new potential PET imaging agents for the DNA repair protein O6-alkylguanine-DNA alkyltransferase in breast cancer.
Triptolide induced DNA damage in A375.S2 human malignant melanoma cells is mediated via reduction of DNA repair genes.
Burkitt Lymphoma
Regulation of O6-methylguanine-DNA methyltransferase expression in the Burkitt's lymphoma cell line Raji.
Carcinogenesis
Alkyltransferase transgenic mice: probes of chemical carcinogenesis.
Associations among smoking, MGMT hypermethylation, TP53-mutations, and relapse in head and neck squamous cell carcinoma.
Both base excision repair and O6-methylguanine-DNA methyltransferase protect against methylation-induced colon carcinogenesis.
Characterization of human polymorphic DNA repair methyltransferase.
Comparison of O6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain.
Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression.
Differential expression of O6-methylguanine-DNA methyltransferase during diethylnitrosamine-induced carcinogenesis and liver regeneration in Sprague-Dawley male rats.
DNA repair: kinetics and thresholds.
Effects of inhibition of O6-alkylguanine-DNA alkyltransferase in rats on carcinogenesis by methylnitrosourea and ethylnitrosourea.
Evaluation of O6-methylguanine DNA methyltransferase activity in patients with gastric cancer.
Gene Promoter Methylation in Endometrial Carcinogenesis.
Genetic and epigenetic alteration profiles for multiple genes in salivary gland carcinomas.
Hypermethylation of CpG island in O6-methylguanine-DNA methyltransferase gene was associated with K-ras G to A mutation in colorectal tumor.
Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma.
Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers.
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.
Induction and purification of O6-methylguanine-DNA-methyltransferase from rat liver.
Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro.
Irradiation-induced expression of O6-methylguanine-DNA methyltransferase in mammalian cells.
Kinetic and DNA-binding properties of recombinant human O6-methylguanine-DNA methyltransferase.
Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach.
Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis.
Methylnitrosourea-induced tumorigenesis in MGMT gene knockout mice.
miR-221-3p promotes hepatocellular carcinogenesis by downregulating O6-methylguanine-DNA methyltransferase.
O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy.
O6-methylguanine-DNA methyltransferase deficiency in developing brain: implications for brain tumorigenesis.
O6-methylguanine-DNA methyltransferase promoter hypermethylation in colorectal carcinogenesis.
Overexpression of DNA methyltransferase 1 (DNMT1) protein in astrocytic tumour and its correlation with O6-methylguanine-DNA methyltransferase (MGMT) expression.
Phosphorylation of methylated-DNA-protein-cysteine S-methyltransferase at serine-204 significantly increases its resistance to proteolytic digestion.
Possible involvement of O6-methylguanine formation and p53 dysfunction in mouse urinary bladder carcinogenesis.
Potentiation of lymphomagenesis by methylnitrosourea in mice transgenic for LMO1 is blocked by O6-alkylguanine DNA-alkyltransferase.
Ras regulation of DNA-methylation and cancer.
Reduced lung tumorigenesis in human methylguanine DNA--methyltransferase transgenic mice achieved by expression of transgene within the target cell.
Repair of DNA lesion O6-methylguanine in hepatocellular carcinogenesis.
Repair of premutagenic DNA lesions in human fetal tissues: evidence for low levels of O6-methylguanine-DNA methyltransferase and uracil-DNA glycosylase activity in some tissues.
Studies in gastric carcinogenesis. IV. O6-methylguanine and its repair in normal and atrophic biopsy specimens of human gastric mucosa. Correlation of O6-alkylguanine-DNA alkyltransferase activities in gastric mucosa and circulating lymphocytes.
Targeted expression of human O(6)-methylguanine-DNA methyltransferase (MGMT) in transgenic mice protects against tumor initiation in two-stage skin carcinogenesis.
The role of O6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis.
Carcinoid Tumor
DNA methylation profiles of lung tumors.
Carcinoma
Clinical significance of epigenetic silencing and re-expression of O6-methylguanine-DNA methyltransferase using epigenetic agents in laryngeal carcinoma.
Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest.
Effect of O6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents.
Effect of TET1 regulating MGMT on chemotherapy resistance of oral squamous cell carcinoma stem cells.
Genetic and epigenetic alteration profiles for multiple genes in salivary gland carcinomas.
Impact of O6-methylguanine-DNA methyltransferase expression on the drug resistance of clear cell renal cell carcinoma.
Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma.
Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers.
Loss expression of O6-methylguanine DNA methyltransferase by promoter hypermethylation and its relationship to betel quid chewing in oral squamous cell carcinoma.
MGMT hypermethylation and BCL-2 overexpression associated with superficial bladder cancer and recurrence.
MGMT promoter methylation is a rare epigenetic change in malignant effusions.
MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo.
O6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide.
O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
Promoter hypermethylation of DNA repair gene MGMT in laryngeal squamous cell carcinoma.
Regulation of O6-methylguanine-DNA methyltransferase by methionine in human tumour cells.
Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.
Smoking-related increase of O6-methylguanine-DNA methyltransferase expression in human lung carcinomas.
Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression.
The effect of o6-methylguanine-DNA methyltransferase (MGMT) and mismatch repair gene (hMLH1) status on the sensitivity to alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea(ACNU) in gallbladder carcinoma cells.
[Promoter hypermethylation of DNA repair gene O6-methylguanine DNA methyltransferase in laryngeal squamous cell carcinoma]
Carcinoma, Hepatocellular
Abnormal intracellular distribution of O6-alkylguanine-DNA-alkyltransferase in hepatitis B cirrhotic human liver: a potential cofactor in the development of hepatocellular carcinoma.
Analysis and modulation of DNA repair in aging.
Combined loss of expression of O6-methylguanine-DNA methyltransferase and hMLH1 accelerates progression of hepatocellular carcinoma.
Constitutive expression and inducibility of O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in rat liver cells exhibiting different status of differentiation.
DNA Alkylating Agent Protects Against Spontaneous Hepatocellular Carcinoma Regardless of O6-Methylguanine-DNA Methyltransferase Status.
Enhancement of 1,3-bis(2-chloroethyl)-1-nitrosourea resistance by gamma-irradiation or drug pretreatment in rat hepatoma cells.
Enhancement of O6-methylguanine-DNA-methyltransferase activity induced by various treatments in mammalian cells.
Extended O6-methylguanine methyltransferase promoter hypermethylation following n-butylidenephthalide combined with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on inhibition of human hepatocellular carcinoma cell growth.
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma.
Increase of O6-methylguanine-DNA-methyltransferase and N3-methyladenine glycosylase RNA transcripts in rat hepatoma cells treated with DNA-damaging agents.
Induced synthesis of O6-methylguanine-DNA methyltransferase in rat hepatoma cells exposed to DNA-damaging agents.
Induction of O6-methylguanine-DNA-methyltransferase and N3-methyladenine-DNA-glycosylase in human cells exposed to DNA-damaging agents.
miR-221-3p promotes hepatocellular carcinogenesis by downregulating O6-methylguanine-DNA methyltransferase.
Potentiation of N-methyl-N'-nitro-N-nitrosoguanidine-induced O6-methylguanine-DNA-methyltransferase activity in a rat hepatoma cell line by poly (ADP-ribose) synthesis inhibitors.
Role of P14 and MGMT gene methylation in hepatocellular carcinomas: a meta-analysis.
Silencing of O6-methylguanine DNA methyltransferase in the absence of promoter hypermethylation in hepatocellular carcinomas from Australia and South Africa.
Stress factors affecting expression of O6-methylguanine-DNA methyltransferase mRNA in rat hepatoma cells.
The capacity of rat hepatoma cell lines for O6-methylguanine-DNA repair correlates with their status of differentiation.
The O6-methylguanine-DNA-methyltransferase activity of rat hepatoma cells is increased after a single exposure to alkylating agents.
Carcinoma, Merkel Cell
MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo.
Carcinoma, Non-Small-Cell Lung
Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Cytological examination of pleural cavity lavage accompanied by the study of gene promoter hypermethylation of p16 and O6-methylguanine-DNA-methyltransferase genes in diagnostics of non-small cell lung cancer metastatic changes into pleura.
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.
Role of O6-methylguanine-DNA methyltransferase, glutathione transferase M3-3 and glutathione in resistance to carmustine in a human non-small cell lung cancer cell line.
[The expression of O6-methylguanine DNA methyltransferase and p53 in non-small cell lung cancer and the association with the prognosis].
Carcinoma, Renal Cell
Impact of O6-methylguanine-DNA methyltransferase expression on the drug resistance of clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
Carcinosarcoma
The promoter methylation and expression of the O6-methylguanine-DNA methyltransferase gene in uterine sarcoma and carcinosarcoma.
Cholelithiasis
[A bicistronic retroviral vector containing MGMT and MDR1 drug resistance genes transfer into human umbilical cord blood CD34+ cells to improve combination chemotherapy tolerance]
Colitis, Ulcerative
Low frequency of promoter methylation of O6-methylguanine DNA methyltransferase and hMLH1 in ulcerative colitis-associated tumors: comparison with sporadic colonic tumors.
The promoter methylation status of the DNA repair gene O6-methylguanine-DNA methyltransferase in ulcerative colitis.
Colonic Neoplasms
Determinants of O6-alkylguanine-DNA alkyltransferase activity in human colon cancer.
DNA Methylation in Human Breast Cancer Cell Lines Adapted to High Nitric Oxide.
O6-Alkylguanine-DNA alkyltransferase in normal colon tissue and colon cancer.
O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
Relationship between DNA adduct levels, repair enzyme, and apoptosis as a function of DNA methylation by azoxymethane.
Colorectal Neoplasms
A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O6-Methylguanine-DNA Methyltransferase Promoter.
Alteration of O6-methylguanine-DNA methyltransferase in colorectal neoplasms in sporadic and familial adenomatous polyposis patients.
Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors.
Clinicopathological significance and potential drug target of O6-methylguanine-DNA methyltransferase in colorectal cancer: a meta-analysis.
Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O(6)-MGMT) promoter regions in colorectal cancer.
DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients.
Effects of Amino Acid Substitution Polymorphisms of two DNA Methyltransferases on Susceptibility to Sporadic Colorectal Cancer.
Germline variation in O6-methylguanine-DNA methyltransferase (MGMT) as cause of hereditary colorectal cancer.
Hypermethylation of CpG island in O6-methylguanine-DNA methyltransferase gene was associated with K-ras G to A mutation in colorectal tumor.
Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases.
Hypermethylation of promoter regions of the APC1A and p16INK4a genes in relation to prognosis and tumor characteristics in cervical cancer patients.
Intramedullary solitary fibrous tumor of dorsal spinal cord.
Low O6-alkylguanine DNA-alkyltransferase activity in normal colorectal tissue is associated with colorectal tumours containing a GC-->AT transition in the K-ras oncogene.
Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach.
Methylation assay by nucleotide incorporation: a quantitative assay for regional CpG methylation density.
Methylation of MGMT and ADAMTS14 in normal colon MUCOSA: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans.
Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers.
MGMT promoter methylation and field defect in sporadic colorectal cancer.
Mutually Exclusive Promoter Hypermethylation Patterns of hMLH1 and O6-Methylguanine DNA Methyltransferase in Colorectal Cancer.
O6-methylguanine-DNA methyltransferase in the defense against N-nitroso compounds and colorectal cancer.
O6-methylguanine-DNA methyltransferase Leu84Phe and Ile143Val polymorphisms and risk of colorectal cancer in the Nurses' Health Study and Physicians' Health Study (United States).
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.
Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma.
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Sensitive and Noninvasive Detection of Aberrant SFRP2 and MGMT-B Methylation in Iranian Patients with Colon Polyps.
Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients.
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
Temozolomide: Mechanisms of Action, Repair and Resistance.
Colorectal Neoplasms, Hereditary Nonpolyposis
Temozolomide: Mechanisms of Action, Repair and Resistance.
Endometrial Neoplasms
Polymorphisms in O6-methylguanine DNA methyltransferase and endometrial cancer risk.
Endometriosis
Immunohistochemical Features of O6-Methylguanine-DNA Methyltransferase Expression during Ovarian Endometriosis.
Ependymoma
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
O6-Methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry.
Epilepsy
Correlation Between Tumor Molecular Markers and Perioperative Epilepsy in Patients With Glioma: A Systematic Review and Meta-Analysis.
Esophageal Neoplasms
Mutations of O6-methylguanine-DNA methyltransferase gene in esophageal cancer tissues from Northern China.
Esophageal Squamous Cell Carcinoma
Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma.
Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.
Fanconi Anemia
Epigenetic deregulation of DNA repair and its potential for therapy.
galactokinase deficiency
Normal expression of thymidine kinase and O6-methylguanine-DNA methyltransferase in cultured fibroblasts from individuals with hereditary galactokinase deficiency.
Galactosemias
Normal expression of thymidine kinase and O6-methylguanine-DNA methyltransferase in cultured fibroblasts from individuals with hereditary galactokinase deficiency.
Gallbladder Neoplasms
Cisplatin represses transcriptional activity from the minimal promoter of the O6-methylguanine methyltransferase gene and increases sensitivity of human gallbladder cancer cells to 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-2-chloroethyl)-3-nitrosourea.
Gastritis
CpG methylation and reduced expression of O6-methylguanine DNA methyltransferase is associated with Helicobacter pylori infection.
Glioblastoma
4-Acetylantrocamol LT3 Inhibits Glioblastoma Cell Growth and Downregulates DNA Repair Enzyme O6-Methylguanine-DNA Methyltransferase.
A "Clickable" Probe for Active MGMT in Glioblastoma Demonstrates Two Discrete Populations of MGMT.
A steroidal saponin form Paris vietnamensis (Takht.) reverses temozolomide resistance in glioblastoma cells via inducing apoptosis through ROS/PI3K/Akt pathway.
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2.
Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin ?5?1 by the Tenascin-C-Derived Peptide TNIIIA2.
An overview of neuro-oncology research and practice in Iran, three years with the NOSC initiative.
Analysis of peritumoral hyperintensity on pre-operative T2-weighted MR images in glioblastoma: Additive prognostic value of Minkowski functionals.
Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.
Anatomical specificity of O6-methylguanine DNA methyltransferase protein expression in glioblastomas.
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.
Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma.
Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
Automatic Prediction of MGMT Status in Glioblastoma via Deep Learning-Based MR Image Analysis.
Bacterial O6-methylguanine-DNA methyltransferase reduces N-methyl-N'-nitro-N-nitrosoguanidine induction of plasminogen activator in Mer- human glioblastoma A1235 cell line.
Basic principles of mathematical growth modeling applied to high-grade gliomas: A brief clinical review for clinicians.
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-?B/MGMT signaling pathway.
Bortezomib Downregulates MGMT Expression in T98G Glioblastoma Cells.
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.
CAT3, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O6-methylguanine DNA methyltransferase expression.
Certain Imidazotetrazines Escape O6-Methylguanine-DNA Methyltransferase and Mismatch Repair.
Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse-A Meta-Analysis Type Literature Review.
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes.
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma.
Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma.
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells.
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme.
Dehydroepiandrosterone Induces Temozolomide Resistance Through Modulating Phosphorylation and Acetylation of Sp1 in Glioblastoma.
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro.
Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples.
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Extensive leptomeningeal intracranial and spinal metastases in a patient with a supratentorial glioblastoma multiforme, IDH-wildtype: A case report.
Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter-hypermethylation - the NCT Neuro Master Match (N2M2) pilot study.
Glioblastoma Recurrence and the Role of O6-Methylguanine-DNA Methyltransferase Promoter Methylation.
Glycogen synthase kinase 3? inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
HIF-1? inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression.
How did lomustine become standard of care in recurrent glioblastoma?
Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma.
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Immunohistochemical and molecular genetics study of a granular cell astrocytoma: A case report of malignant transformation to a glioblastoma.
Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma.
In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
Incorporating molecular tools into clinical trials and treatment for gliomas?
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Induction of the DNA repair gene O6-methylguanine-DNA methyltransferase by dexamethasone in glioblastomas.
Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Integrative analysis of DNA methylation suggests down-regulation of oncogenic pathways and reduced somatic mutation rates in survival outliers of glioblastoma.
Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis.
Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Machine learning-based radiomic, clinical and semantic feature analysis for predicting overall survival and MGMT promoter methylation status in patients with glioblastoma.
Magnetic Resonance Imaging Reveals a Pronounced Treatment Response of a Isocitrate Dehydrogenase- and B-Raf Proto-Oncogene-Wildtype Epithelioid Glioblastoma.
Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital.
Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
MGMT Gene Promoter Methylation Status - Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas.
MGMT immunohistochemical expression and promoter methylation in human glioblastoma.
MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.
MGMT promoter methylation in gliomas - assessment by pyrosequencing and quantitative methylation-specific PCR.
MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
MGMT Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features.
MGMT Promoter Methylation Status Is Not Related to Histological or Radiological Features in IDH Wild-type Glioblastomas.
miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase.
miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma.
Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma.
Molecular classification of gliomas.
Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers.
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
MRI Atlas of IDH Wild-Type Supratentorial Glioblastoma: Probabilistic Maps of Phenotype, Management, and Outcomes.
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcoma.
O6-Methylguanine-DNA Methyltransferase is a Novel Negative Effector of Invasion in Glioblastoma Multiforme.
O6-methylguanine-DNA methyltransferase promoter methylation and isocitrate dehydrogenase mutation as prognostic factors in a cohort of Saudi patients with glioblastoma.
O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells.
Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma.
Outlining involvement of stem cell program in regulation of O6-methylguanine DNA methyltransferase and development of temozolomide resistance in glioblastoma: An Editorial Highlight for 'Transcriptional control of O6 -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma' on page 780.
PARP inhibition suppresses the emergence of temozolomide resistance in a model system.
PARP mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Phenytoin may increase the efficacy of temozolomide by methylating DNA-repair enzyme, O6-methylguanine-DNA methyltransferase in patients with glioblastoma.
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma.
Predicting MGMT Promoter Methylation of Glioblastoma from Dynamic Susceptibility Contrast Perfusion: A Radiomic Approach.
Prediction of MGMT Status for Glioblastoma Patients Using Radiomics Feature Extraction From 18F-DOPA-PET Imaging.
Predictive markers for MGMT promoter methylation in glioblastomas.
Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes.
Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.
Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.
Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Prognostic Value of MGMT Promoter Methylation and TP53 Mutation in Glioblastomas Depends on IDH1 Mutation.
Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O6-Methylguanine-DNA Methyltransferase, Cyclin-D1, and p53.
Pyrosequencing Analysis of MGMT Promoter Methylation in Meningioma.
Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.
Radiation therapy for older adults with glioblastoma: radical treatment, palliative treatment, or no treatment at all?
Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial.
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Recurrent high-grade glioma.
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Regulation of O6-methylguanine-DNA methyltransferase by methionine in human tumour cells.
Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis.
Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.
Role of postoperative tumor volume in patients with MGMT-unmethylated glioblastoma.
Role of temozolomide in pediatric brain tumors.
Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis.
Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
Temozolomide Induces the Acquisition of Invasive Phenotype by O6-Methylguanine-DNA Methyltransferase (MGMT)+ Glioblastoma Cells in a Snail-1/Cx43-Dependent Manner.
Temozolomide plus radiotherapy for glioblastoma in a Canadian province: Efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Temozolomide: Mechanisms of Action, Repair and Resistance.
The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis.
The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model.
The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status.
The effect of race on the prognosis of the glioblastoma patient: a brief review.
The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma.
The Multipotential of Leucine-Rich ?-2 Glycoprotein 1 as a Clinicopathological Biomarker of Glioblastoma.
The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis.
The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power.
The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma.
Therapy and progression - induced O6-methylguanine-DNA methyltransferase and mismatch repair alterations in recurrent glioblastoma multiforme.
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
[Interdisciplinary neuro-oncology: part 1: diagnostics and operative therapy of primary brain tumors].
[Interdisciplinary neuro-oncology: part 2: systemic therapy of primary brain tumors].
[O6-methylguanine-DNA-methyltransferase (MGMT) expression in patients with glioblastoma multiforme].
Glioma
18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma.
?-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
A comparative immunohistochemistry of O6-methylguanine-DNA methyltransferase and p53 in diffusely infiltrating astrocytomas.
A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide.
A three-dimensional collagen scaffold cell culture system for screening anti-glioma therapeutics.
Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
An overview of neuro-oncology research and practice in Iran, three years with the NOSC initiative.
Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo.
Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multi-pool CEST MRI at 7.0 Tesla.
BCL3 expression promotes resistance to alkylating chemotherapy in gliomas.
Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
Case Report: Clinical Outcome and Image Response of Two Patients With Secondary High-Grade Glioma Treated With Chemoradiation, PCV, and Cannabidiol.
Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue.
Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients.
Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population.
Clk1-regulated aerobic glycolysis is involved in glioma chemoresistance.
Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide).
Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study.
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.
Diffusion kurtosis imaging combined with molecular markers as a comprehensive approach to predict overall survival in patients with gliomas.
Direct, real-time PCR (MethyLight) assay for methylation of O6-methylguanine-DNA methyltransferase promoter in glioma.
Disruption of NF-?B signaling by fluoxetine attenuates MGMT expression in glioma cells.
DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase.
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
DNA Repair Polymorphisms XRCC1 and MGMT and Risk of Adult Gliomas.
Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma.
Down-regulation of O6-methylguanine-DNA methyltransferase gene expression in gliomas by platinum compounds.
Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.
Effects of valproic acid on the susceptibility of human glioma stem cells for TMZ and ACNU.
Elevated expression of DNA polymerase beta gene in glioma cell lines with acquired resistance to 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3- nitrosourea.
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.
Ex vivo ultrasonic samples of human brain tumors in the molecular era.
Expression and clinical significance of P53, O6-methylguanine-dna methyltransferase and epidermal growth factor receptor in glioma.
Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines.
Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity.
Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas.
Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line.
Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells.
High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase.
Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.
Immunohistochemical expression of MGMT in Gliomas.
Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas.
Impact of MTHFR polymorphisms on methylation of MGMT in glioma patients from Northeast China with different folate levels.
Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.
Inhibition of NF-?B results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation.
Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy.
Interrelationship between O6-alkylguanine-DNA alkyltransferase activity and susceptibility to chloroethylnitrosoureas in several glioma cell lines.
Involvement of N-methylpurine DNA glycosylase in resistance to temozolomide in patient-derived glioma cells.
Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Lack of expression of tumor-suppressor genes in human malignant glioma cell lines.
Lower apparent diffusion coefficients indicate distinct prognosis in low-grade and high-grade glioma.
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review.
Methylation Status of the O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Gene Promoter in World Health Organization Grade III Gliomas.
MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NF?B and mutant p53.
MGMT-Methylation in Non-Neoplastic Diseases of the Central Nervous System.
MGMT: Immunohistochemical Detection in High-Grade Astrocytomas.
Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.
Molecular characteristics of pediatric non-ependymal, non?pilocytic gliomas associated with resistance to temozolomide.
Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers.
Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase.
Molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient's prognosis.
MRI-Based Deep-Learning Method for Determining Glioma MGMT Promoter Methylation Status.
Multi-Label Nonlinear Matrix Completion With Transductive Multi-Task Feature Selection for Joint MGMT and IDH1 Status Prediction of Patient With High-Grade Gliomas.
New treatment paradigm for patients with anaplastic oligodendroglial tumors.
O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications.
O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas.
O6-benzylguanine-mediated enhancement of chemotherapy.
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy.
O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics.
O6-methylguanine-DNA methyltransferase activity in cerebral gliomas. A guidance for nitrosourea treatment?
O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.
O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival.
Perillyl Alcohol (POH) For the Treatment of Temozolomide-Resistant Gliomas.
Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide.
Predicting O6-Methylguanine-DNA Methyltransferase Protein Expression in Primary Low- and High-Grade Gliomas Using Certain Qualitative Characteristics of Amide Proton Transfer-Weighted Magnetic Resonance Imaging.
Predictive value of MGMT promoter methylation status in Asian and Caucasian patients with malignant gliomas: a meta-analysis.
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.
Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes.
Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Quantitation of O6-methylguanine-DNA methyltransferase gene messenger RNA in gliomas by means of real-time RT-PCR and clinical response to nitrosoureas.
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.
Receptor tyrosine kinase expression in high-grade gliomas before and after chemoradiotherapy.
Rechallenge with temozolomide in recurrent glioma.
Regulation of temozolomide resistance in glioma cells via the RIP2/NF-?B/MGMT pathway.
Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients.
Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.
Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas.
Silencing of MGMT with small interference RNA reversed resistance in human BCUN-resistant glioma cell lines.
Survival in patients with newly diagnosed conventional glioblastoma: a modified prognostic score based on a single-institution series.
Synthesis and growth-inhibitory activities of imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position.
Targeting transferrin receptor delivery of temozolomide for a potential glioma stem cell-mediated therapy.
Temozolomide in combination with carbon ion or photon irradiation in glioblastoma multiforme cell lines - does scheduling matter?
The ABCG2 resistance network of glioblastoma.
The association between 11C-methionine uptake, IDH gene mutation, and MGMT promoter methylation in patients with grade II and III gliomas.
The correlation between promoter methylation status and the expression level of O6-methylguanine-DNA methyltransferase in recurrent glioma.
The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
The role of APT imaging in gliomas grading: A systematic review and meta-analysis.
Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
Updates in prognostic markers for gliomas.
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.
[Biomarkers in high-grade gliomas: A systematic review].
[Circumvention of ACNU-resistance in rat glioma cells by pretreatment with O6-methylguanine]
[Clinicopathological diagnosis of gliomas by genotype analysis]
[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma.]
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases]
[Interdisciplinary neuro-oncology: part 1: diagnostics and operative therapy of primary brain tumors].
[Interdisciplinary neuro-oncology: part 2: systemic therapy of primary brain tumors].
[Relationship between the expression of O6-methylguanine-DNA methyltransferase in glioma and the survival time of patients]
Gliosarcoma
A study of clinico-pathological parameters and O(6) - methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
Clinicopathologic and genomic features of gliosarcomas.
The prognostic impact of O6-methylguanine DNA methyltransferase and epidermal growth factor receptor expressions on primary gliosarcoma: a clinicopathologic and immunohistochemical study of seven cases at a single institution.
Head and Neck Neoplasms
Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients.
Hematologic Neoplasms
Hypermethylation of the putative tumor-suppressor genes DCC, p51/63 and O6-methylguanine-DNA methyltransferase (MGMT) and loss of their expressions in cell lines of hematological malignancies.
Hepatitis, Chronic
Cell type-specific induction of O6-alkylguanine-DNA alkyltransferase mRNA expression in rat liver during regeneration, inflammation and preneoplasia.
Herpes Simplex
Relationships among cell survival, O6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adenovirus 5 and herpes simplex virus type 1 in human melanoma cell lines.
Hodgkin Disease
Expression of O6-alkylguanine-DNA-alkyltransferase in situ in ovarian and Hodgkin's tumours.
Heterogeneity of O6-alkylguanine-DNA alkyltransferase activity in peripheral blood lymphocytes: relationship between this activity in lymphocytes and in lymphoblastoid lines from normal controls and from patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells.
Hypersensitivity
Coregulation of the human O6-methylguanine-DNA methyltransferase with two unrelated genes that are closely linked.
Hypersensitivity of human tumor xenografts lacking O6-alkylguanine-DNA alkyltransferase to the anti-tumor agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitros ourea.
Infections
CpG methylation and reduced expression of O6-methylguanine DNA methyltransferase is associated with Helicobacter pylori infection.
Relationships among cell survival, O6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adenovirus 5 and herpes simplex virus type 1 in human melanoma cell lines.
Intellectual Disability
Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Laryngeal Neoplasms
Detection of O6-methylguanine-DNA methyltransferase gene promoter region methylation pattern using pyrosequencing and the effect of methylation pattern on survival, recurrence, and chemotherapy sensitivity in patients with laryngeal cancer.
Leiomyosarcoma
Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series.
Leukemia
Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU.
Increase in nitrosourea resistance in mammalian cells by retrovirally mediated gene transfer of bacterial O6-alkylguanine-DNA alkyltransferase.
Low O6-alkylguanine DNA alkyltransferase activity in the peripheral blood lymphocytes of patients with therapy-related acute nonlymphocytic leukemia.
O6-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia.
O6-Alkylguanine-DNA alkyltransferase content in synchronised human cancer cells.
O6-methylguanine as a modulator of antitumor activity of N-alkyl-N-nitrosoureas in vivo.
Patterns of drug resistance parameters in adult leukemia.
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Potentiation of nitrosourea cytotoxicity in human leukemic cells by inactivation of O6-alkylguanine-DNA alkyltransferase.
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines.
Leukemia, Lymphoid
O6-alkylguanine-DNA alkyltransferase activity in blasts obtained from patients with myelogenous or lymphocytic leukemia.
Leukemia, Myeloid
Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.
Leukemia, Myeloid, Acute
Low O6-alkylguanine DNA alkyltransferase activity in the peripheral blood lymphocytes of patients with therapy-related acute nonlymphocytic leukemia.
O6-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia.
Leukopenia
Leukopenia is a biomarker for effective temozolomide dosing and predicts overall survival of patients with glioblastoma.
Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity.
Liver Diseases
Effect of alcohol drinking on gene expression of hepatic O6-methylguanine DNA methyltransferase in chronic liver diseases.
Lung Neoplasms
Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Association between lung cancer risk and single nucleotide polymorphisms in the first intron and codon 178 of the DNA repair gene, O6-alkylguanine-DNA alkyltransferase.
Association between O6-alkylguanine-DNA-alkyltransferase activity in peripheral blood lymphocytes and bronchial epithelial cells.
Association of genetic variants of O6-methylguanine-DNA methyltransferase with risk of lung cancer in non-Hispanic Whites.
Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Association of the Promoter Methylation and the rs12917 Polymorphism of MGMT with Formation of DNA Bulky Adducts and the Risk of Lung Cancer in Mexican Mestizo Population.
Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines.
Cytological examination of pleural cavity lavage accompanied by the study of gene promoter hypermethylation of p16 and O6-methylguanine-DNA-methyltransferase genes in diagnostics of non-small cell lung cancer metastatic changes into pleura.
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.
Determinants of a genotoxic effect of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human diploid fibroblasts.
DNA methylation profiles of lung tumors.
Exon 5 polymorphisms in the O6-alkylguanine DNA alkyltransferase gene and lung cancer risk in non-smokers exposed to second-hand smoke.
O6-alkylguanine-DNA alkyltransferase gene polymorphisms and the risk of primary lung cancer.
O6-Methylguanine-DNA methyltransferase hypermethylation modulated by 17beta-estradiol in lung cancer cells.
Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer.
Reduced O6-methylguanine repair in fibroblast cultures from patients with lung cancer.
Role of O6-methylguanine-DNA methyltransferase, glutathione transferase M3-3 and glutathione in resistance to carmustine in a human non-small cell lung cancer cell line.
Role of polymorphisms in codons 143 and 160 of the O6-alkylguanine DNA alkyltransferase gene in lung cancer risk.
[A study on the role of DNA repair gene O6-methylguanine-DNA methyltransferase in the development of human lung cancer]
[Aberrant promoter methylation of tumor suppressor genes in serum from lung cancer patients: frequency and correlation with clinicopathological characteristics]
[The expression of O6-methylguanine DNA methyltransferase and p53 in non-small cell lung cancer and the association with the prognosis].
Lymphoma
Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas.
O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.
Overexpression of human O6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice.
Possible depletion of a DNA repair enzyme in human lymphoma cells by subversive repair.
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.
Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
Rapid repair of O6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas.
The immature thymocyte is protected from N-methylnitrosourea-induced lymphoma by the human MGMT-CD2 transgene.
The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase.
Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon.
Lymphoma, B-Cell
Determination of apoptosis, proliferation status and O6-methylguanine DNA methyltransferase methylation profiles in different immunophenotypic profiles of diffuse large B-cell lymphoma.
Epigenetic changes and their clinical relevance in Saudi diffuse large B-cell lymphoma. A molecular and tissue microarray analysis of 100 cases.
High frequency and strong prognostic relevance of O6-methylguanine DNA methyltransferase silencing in diffuse large B-cell lymphomas from the Middle East.
Is inactivation of O(6)-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?
Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma.
Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase.
MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression.
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.
Prognostic significance of O6-methylguanine DNA methyltransferase and p57 methylation in patients with diffuse large B-cell lymphomas.
Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Determination of apoptosis, proliferation status and O6-methylguanine DNA methyltransferase methylation profiles in different immunophenotypic profiles of diffuse large B-cell lymphoma.
Epigenetic changes and their clinical relevance in Saudi diffuse large B-cell lymphoma. A molecular and tissue microarray analysis of 100 cases.
Is inactivation of O(6)-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?
Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma.
MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression.
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.
Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
Lymphoma, Non-Hodgkin
Heterogeneity of O6-alkylguanine-DNA alkyltransferase activity in peripheral blood lymphocytes: relationship between this activity in lymphocytes and in lymphoblastoid lines from normal controls and from patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Lymphoma, T-Cell, Cutaneous
Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents.
Phase I Clinical Trial of O6-Benzylguanine and Topical Carmustine in the Treatment of Cutaneous T-Cell Lymphoma, Mycosis Fungoides Type.
Lymphopenia
Impact of temozolomide on immune response during malignant glioma chemotherapy.
Medulloblastoma
Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2'-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea.
Expression of O6-methylguanine-DNA methyltransferase in six human medulloblastoma cell lines.
O6-alkylguanine DNA-alkyltransferase is not a major determinant of sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea in four medulloblastoma cell lines.
Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes.
Regulation of O6-methylguanine-DNA methyltransferase by methionine in human tumour cells.
Melanoma
A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models.
A single cycle of treatment with temozolomide, alone or combined with O6-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O6-methylguanine-DNA methyltransferase and the mismatch repair system.
Acquired resistance to 6-thioguanine in melanoma cells involves the repair enzyme O6-methylguanine-DNA methyltransferase (MGMT).
Analysis of O6-methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction.
Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.
Disposition and metabolism of O6-alkylguanine-DNA alkyltransferase inhibitor in nude mice bearing human melanoma.
DNA damage induced by a new 2-chloroethyl nitrosourea on malignant melanoma cells.
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance.
Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy.
Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases.
Immunohistological examination of the inter- and intracellular distribution of O6-alkylguanine DNA-alkyltransferase in human liver and melanoma.
In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.
Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma.
Inhibition of O6-alkylguanine-DNA alkyltransferase by O6-benzyl-N2-acetylguanosine increases chloroethylnitrosourea-induced apoptosis in Mer+ human melanoma cells.
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Novel O6-methylguanine-DNA methyltransferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden.
O6-alkylguanine-DNA alkyltransferase activity in human malignant melanoma.
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine.
O6-methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours.
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.
O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
Reduced O6-methylguanine repair in fibroblast cultures from patients with lung cancer.
Relationships among cell survival, O6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adenovirus 5 and herpes simplex virus type 1 in human melanoma cell lines.
Relationships between the formation of O6-methyldeoxyguanosine by 1-p-carboxyl-3,3-dimethylphenyltriazene in DNA and O6-alkylguanine-DNA alkyltransferase in human peripheral leukocytes.
Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis.
The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin.
The role of O6-methylguanine-DNA methyltransferase in a long-surviving metastatic melanoma.
Melanoma, Experimental
O6-methylguanine as a modulator of antitumor activity of N-alkyl-N-nitrosoureas in vivo.
methylated-dna-[protein]-cysteine s-methyltransferase deficiency
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
O6-methylguanine-DNA methyltransferase deficiency in developing brain: implications for brain tumorigenesis.
SNP rs16906252C>T is an expression and methylation quantitative trait locus associated with an increased risk of developing MGMT-methylated colorectal cancer.
Transfection of murine multi-potent haemopoietic stem cells with an E. coli DNA alkyltransferase gene confers resistance to the toxic effects of alkylating agents.
Mouth Neoplasms
Aberrant DNA methylation of tumor-related genes in oral rinse: A noninvasive method for detection of oral squamous cell carcinoma.
Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines.
Influence of CpG island methylation status in O6-methylguanine-DNA methyltransferase expression of oral cancer cell lines.
Role of O6-methylguanine-DNA methyltransferase and effect of O6-benzylguanine on the anti-tumor activity of cis-diaminedichloroplatinum(II) in oral cancer cell lines.
Multiple Myeloma
O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.
Mycosis Fungoides
Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
Nasopharyngeal Carcinoma
O6-methylguanine-DNA methyltransferase modulates cisplatin-induced DNA double-strand breaks by targeting the homologous recombination pathway in nasopharyngeal carcinoma.
Ubiquitin-conjugating enzyme E2 B regulates the ubiquitination of O6-methylguanine-DNA methyltransferase and BCNU sensitivity in human nasopharyngeal carcinoma cells.
[Correlation of O6-methylguanine-DNA methyltransferase to radiation sensitivity of nasopharyngeal carcinoma.]
Neoplasm Metastasis
Analysis of O6-methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction.
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.
Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy.
Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases.
O6-methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours.
Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential.
Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients.
Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression.
Neoplasm, Residual
Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma.
The Role of Delayed Radiotherapy Initiation in Patients with Newly Diagnosed Glioblastoma with Residual Tumor Mass.
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Neoplasms
3-Bromopyruvate regulates the status of glycolysis and BCNU sensitivity in human hepatocellular carcinoma cells.
A 4-miRNA signature to predict survival in glioblastomas.
A comparative immunohistochemistry of O6-methylguanine-DNA methyltransferase and p53 in diffusely infiltrating astrocytomas.
A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma.
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.
A polymorphism at codon 160 of human O6-methylguanine-DNA methyltransferase gene in young patients with adult type cancers and functional assay.
A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine.
A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms.
Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer.
Abnormal MGMT Promoter Methylation in Gastrointestinal Stromal Tumors: Genetic Susceptibility and Association with Clinical Outcome.
Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Activity of the DNA repair protein O6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue.
Adaptive Radiotherapy for Glioblastoma Multiforme - The Impact on Disease Outcome.
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.
Affinity purification and characterization of human O6-alkylguanine-DNA alkyltransferase complexed with BCNU-treated, synthetic oligonucleotide.
Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells.
Altered O6-alkylguanine-DNA alkyltransferase activity in cell strains originating from mouse skin tumors induced by UV irradiation.
Analysis of N-methyl-N-nitrosourea-induced mutations in a shuttle vector plasmid propagated in mouse O6-methylguanine-DNA methyltransferase-deficient cells in comparison with proficient cells.
Analysis of O6-methylguanine-DNA methyltransferase in individual human cells by quantitative immunofluorescence microscopy.
Analysis of peritumoral hyperintensity on pre-operative T2-weighted MR images in glioblastoma: Additive prognostic value of Minkowski functionals.
Analysis of risk factors and clinical sequelae of direct electrical cortical stimulation-induced seizures and afterdischarges in patients undergoing awake mapping.
Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.
Antiproliferative Activity of a New Nitrosyl Iron Complex with Cysteamine in Human Tumor Cells In Vitro.
Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.
Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.
Basic principles of mathematical growth modeling applied to high-grade gliomas: A brief clinical review for clinicians.
BCL3 expression promotes resistance to alkylating chemotherapy in gliomas.
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL.
Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
Bortezomib Downregulates MGMT Expression in T98G Glioblastoma Cells.
Boswellic acid activity against glioblastoma stem-like cells.
Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics.
Characterization and chemosensitivity of two cell lines derived from human glioblastomas.
Characterization of a novel HHV-8-positive cell line reveals implications for the pathogenesis and cell cycle control of primary effusion lymphoma.
Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes.
Chromosome arm 1q gain associated with good response to chemotherapy in a malignant glioma. Case report.
Clinical and molecular features of mucosa-associated lymphoid tissue (MALT) lymphomas of salivary glands.
Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.
Coaxial extrusion bioprinted shell-core hydrogel microfibers mimic glioma microenvironment and enhance the drug resistance of cancer cells.
Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Comparison of DNA interstrand cross-linking and strand breakage by 1,3-bis(2-chloroethyl)-1-nitrosourea in polyamine-depleted and control human adenocarcinoma cells.
Comparison of O6-methylguanine-DNA methyltransferase mRNA levels in Ha-ras mutated and non-mutated rat mammary tumors induced by N-methyl-N-nitrosourea.
Correlation between DNA methylation and expression of O6-methylguanine-DNA methyltransferase gene in cultured human tumor cells.
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma.
Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression.
CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration.
Creation of human alkyltransferases resistant to O6-benzylguanine.
Curcumin Administered as Micellar Solution Suppresses Intestinal Inflammation and Colorectal Carcinogenesis.
Cytochrome P-450 isozyme pattern is related to individual susceptibility to diethylnitrosamine-induced liver cancer in rats.
Cytoplasmic sequestration of an O6-methylguanine-DNA methyltransferase enhancer binding protein in DNA repair-deficient human cells.
Cytosine methylation and suppression of O6-methylguanine-DNA methyltransferase expression in human rhabdomyosarcoma cell lines and xenografts.
Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells.
Dealkylation rates of O6-alkyldeoxyguanosine, O4-alkylthymidine and related compounds in an alkyl-transfer system.
Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine.
Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.
Detection of messenger RNA from O6-methylguanine-DNA methyltransferase gene MGMT in human normal and tumor tissues.
Detection of O6-methylguanine-DNA methyltransferase gene promoter region methylation pattern using pyrosequencing and the effect of methylation pattern on survival, recurrence, and chemotherapy sensitivity in patients with laryngeal cancer.
Detection of O6-methylguanine-DNA methyltransferase-expression in human tumors by means of in situ hybridization.
Determinants of O(6)-alkylguanine-DNA alkyltransferase activity in normal and tumour tissue from human colon and rectum.
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Development and application of a multiplex PCR procedure for the detection of DNA methylation in colorectal cancer.
Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy.
Differential inactivation of O6-methylguanine-DNA methyltransferase activity by O6-arylmethylguanines.
Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
Differential sensitivity of human and mouse alkyltransferase to O6-benzylguanine using a transgenic model.
Diffusion kurtosis imaging combined with molecular markers as a comprehensive approach to predict overall survival in patients with gliomas.
Disappearance of gadolinium enhancement in a chemoresistant astrocytoma of the tectum after high-dose interferon beta.
Disposition and metabolism of O6-alkylguanine-DNA alkyltransferase inhibitor in nude mice bearing human melanoma.
Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy.
DNA damage and repair measured in different genomic regions using the comet assay with fluorescent in situ hybridization.
DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients.
DNA methylation profiles of lung tumors.
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system.
DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents.
Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.
Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21.
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer.
Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.
Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma.
Effects of O6-methylguanine-DNA methyltransferase (MGMT) polymorphisms on cancer: a meta-analysis.
EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
Elderly patients with glioblastoma: the treatment challenge.
Enhanced O6-methylguanine-DNA alkyltransferase activity in rat liver nodules.
Enhancement by O6-benzyl-N2-acetylguanosine of N'-[2-chloroethyl]-N-[2-(methylsulphonyl)ethyl]-N'-nitrosourea therapeutic index on nude mice bearing resistant human melanoma.
Enhancement effect of O6-fluorobenzylguanines on chloroethylnitrosourea cytotoxicity in tumor cells.
Epigenetic aberrations and therapeutic implications in gliomas.
Epigenetic changes and their clinical relevance in Saudi diffuse large B-cell lymphoma. A molecular and tissue microarray analysis of 100 cases.
Epigenetic deregulation of DNA repair and its potential for therapy.
Epigenetic regulation of DNA repair genes and implications for tumor therapy.
Epigenetic silencing of the MGMT gene in cancer.
Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2'-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea.
Evaluation of O6-methylguanine DNA methyltransferase activity in patients with gastric cancer.
Evidence for nucleotide excision repair as a modifying factor of O6-methylguanine-DNA methyltransferase-mediated innate chloroethylnitrosourea resistance in human tumor cell lines.
Exon 3 polymorphisms and haplotypes of O6-methylguanine-DNA methyltransferase and risk of bladder cancer in southern China: a case-control analysis.
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
Expression and clinical significance of P53, O6-methylguanine-dna methyltransferase and epidermal growth factor receptor in glioma.
Expression and prognostic significance of O6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers.
Expression of O6-alkylguanine-DNA-alkyltransferase in situ in ovarian and Hodgkin's tumours.
Expression of O6-methylguanine-deoxyribose nucleic acid methyltransferase and temozolomide response in a patient with a malignant spinal cord astrocytoma. Case report.
Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines.
Expression of ribosomal phosphoprotein PO is induced by antitumor agents and increased in Mer- human tumor cell lines.
Expression of the O6-alkylguanine-DNA alkyltransferase gene is elevated in human breast tumor cells.
Expression of the O6-methylguanine-DNA methyltransferase gene in eight human tumor cell lines.
Expression of the O6-methylguanine-DNA methyltransferase gene MGMT in MER+ and MER- human tumor cells.
Fluorescent reporter assays provide direct, accurate, quantitative measurements of MGMT status in human cells.
Focus on Fotemustine.
Formation and persistence of O(6)-methylguanine in the mouse colon following treatment with 1,2-dimethylhydrazine as measured by an O(6)-alkylguanine-DNA alkyltransferase inactivation assay.
Formation of covalent complexes between human O6-alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides.
Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study.
Gene promoter hypermethylation in tumors and serum of head and neck cancer patients.
Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer.
Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone.
Glioblastoma multiforme: a review of where we have been and where we are going.
Glioblastoma: from volumetric analysis to molecular predictors.
Glioma therapy in adults.
Glutathione S-transferase and O6-methylguanine DNA methyl transferase activities in patients with thyroid papillary carcinoma.
Glycolytic inhibition by 3-bromopyruvate increases the cytotoxic effects of chloroethylnitrosoureas to human glioma cells and the DNA interstrand cross-links formation.
Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours.
Host determinants of DNA alkylation and DNA repair activity in human colorectal tissue: O(6)-methylguanine levels are associated with GSTT1 genotype and O(6)-alkylguanine-DNA alkyltransferase activity with CYP2D6 genotype.
How did lomustine become standard of care in recurrent glioblastoma?
Hypersensitivity of human tumor xenografts lacking O6-alkylguanine-DNA alkyltransferase to the anti-tumor agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitros ourea.
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.
Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma.
Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy.
Immunohistochemical assessment of MGMT expression and p53 mutation in glioblastoma multiforme.
Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases.
Immunohistochemical expression of MGMT in Gliomas.
Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway.
In situ detection of O6-methylguanine-DNA methyltransferase messenger RNA in paraffin-embedded human astrocytic tumor tissues by nested in situ RT-PCR is useful in predicting chemotherapy-resistance of tumors.
In vitro methylation of the human O6-methylguanine-DNA methyltransferase promoter reduces transcription.
In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.
In vivo effects of myeloablative alkylator therapy on survival and differentiation of MGMTP140K-transduced human G-CSF-mobilized peripheral blood cells.
Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2'-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine.
Inactivation of O6-methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by O6-methylguanine as a free base.
Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers.
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea.
Increasing DNA repair capacity in bone marrow by gene transfer as a prospective tool in cancer therapy.
Induction of the DNA repair gene O6-methylguanine-DNA methyltransferase by dexamethasone in glioblastomas.
Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide.
Inhibition of O6-alkylguanine-DNA alkyltransferase in animal and human ovarian tumor cell lines by O6-benzylguanine and sensitization to BCNU.
Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy.
Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma.
Interferon inducers increase O6-alkylguanine-DNA alkyltransferase in the rat liver.
Interferon-beta does not change the level of O6-alkylguanine-DNA alkyltransferase in cancer patients' lymphocytes.
Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Intramedullary solitary fibrous tumor of dorsal spinal cord.
Intraoperative molecular margin analysis in head and neck cancer.
Investigation of chemoresistance-related genes mRNA expression for selecting anticancer agents in successful adjuvant chemotherapy for a case of recurrent glioblastoma.
Involvement of N-methylpurine DNA glycosylase in resistance to temozolomide in patient-derived glioma cells.
Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series.
Is Visible Aminolevulinic Acid-Induced Fluorescence an Independent Biomarker for Prognosis in Histologically Confirmed (World Health Organization 2016) Low-Grade Gliomas?
JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
Key determinants of short-term and long-term glioblastoma survival: a 14-year retrospective study of patients from the Hermelin Brain Tumor Center at Henry Ford Hospital.
Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer.
Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors.
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Low frequency of promoter methylation of O6-methylguanine DNA methyltransferase and hMLH1 in ulcerative colitis-associated tumors: comparison with sporadic colonic tumors.
Low O6-alkylguanine DNA alkyltransferase activity in the peripheral blood lymphocytes of patients with therapy-related acute nonlymphocytic leukemia.
Low O6-alkylguanine DNA-alkyltransferase activity in normal colorectal tissue is associated with colorectal tumours containing a GC-->AT transition in the K-ras oncogene.
Management of diffusely infiltrating glioma in the elderly.
Measurement of O6-alkylguanine-DNA alkyltransferase activity in human cells and tumor tissues by restriction endonuclease inhibition.
Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide.
Melanoma-cell toxicity of cystemustine combined with O6-benzyl-N2-acetylguanosine.
Metabolism and disposition of O6-benzyl-2'-deoxyguanosine in Sprague-Dawley rats.
Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene.
Methylation of selected CpGs in the human O6-methylguanine-DNA methyltransferase promoter region as a marker of gene silencing.
Methylation of the O6-methylguanine-DNA methyltransferase promoter suppresses expression in mouse skin tumors and varies with the tumor induction protocol.
MGMT hypermethylation and BCL-2 overexpression associated with superficial bladder cancer and recurrence.
MGMT Is a Molecular Determinant for Potency of the DNA-EGFR-Combi-Molecule ZRS1.
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
Microsatellite instability is infrequent in sporadic adult gliomas.
Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine.
Modulation of 1,3-bis-(2-chloroethyl)-1-nitrosourea resistance in human tumor cells using hammerhead ribozymes designed to degrade O6-methylguanine DNA methyltransferase mRNA.
Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.
Modulation of nitrosourea resistance in myeloid leukemias.
Modulation of O6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers.
Modulation of O6-methylguanine-DNA methyltransferase-mediated 1-(4-amino-2-methyl-5-Pyrimidinyl)- methyl-3-(2-Chloroethyl)-3-nitrosourea resistance by antisense RNA.
Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma.
Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers.
MSI2-TGF-?/TGF-? R1/SMAD3 positive feedback regulation in glioblastoma.
mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells.
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.
Multiple drug resistance parameter expression in ovarian cancer.
Non-functioning pituitary tumors: 2012 update.
Novel multi-drugs incorporating hybrid-structured nanofibers enhance alkylating agent activity in malignant gliomas.
Novel post DNA synthesis chemistry for preparing oligonucleotides containing O6-modified purines.
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
O-6-alkylguanine-DNA alkyltransferase activity in tissues of mice treated with antischistosomal agents.
O6-alkylguanine DNA-alkyltransferase is not a major determinant of sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea in four medulloblastoma cell lines.
O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea.
O6-alkylguanine-DNA alkyltransferase activity in epidermal tumor and normal epidermal cells of mice of various stocks and strains.
O6-alkylguanine-DNA alkyltransferase activity in human brain tumors.
O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications.
O6-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia.
O6-Alkylguanine-DNA alkyltransferase content in synchronised human cancer cells.
O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents.
O6-alkylguanine-DNA alkyltransferase inactivation by ester prodrugs of O6-benzylguanine derivatives and their rate of hydrolysis by cellular esterases.
O6-alkylguanine-DNA alkyltransferase inactivation in cancer chemotherapy.
O6-benzylguanine and its role in chemotherapy.
O6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide.
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
O6-methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms.
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
O6-methylguanine methyltransferase activity and sensitivity of Japanese tumor cell strains to 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)- 3-nitrosourea hydrochloride.
O6-methylguanine repair by O6-alkylguanine-DNA alkyltransferase.
O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
O6-methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours.
O6-methylguanine-DNA methyltransferase activity and induction of novel immunogenicity in murine tumor cells treated with methylating agents.
O6-methylguanine-DNA methyltransferase activity and promoter methylation status in pediatric rhabdomyosarcoma.
O6-methylguanine-DNA methyltransferase activity and sensitivity of human tumor cell lines to bis-chloroethylnitrosourea.
O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts.
O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics.
O6-methylguanine-DNA methyltransferase activity in breast and brain tumors.
O6-methylguanine-DNA methyltransferase activity in human liver tumors.
O6-methylguanine-DNA methyltransferase activity in human tumors.
O6-methylguanine-DNA methyltransferase and human cancer chemotherapy.
O6-Methylguanine-DNA methyltransferase in human cells.
O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary.
O6-methylguanine-DNA methyltransferase in normal and malignant tissue of the breast.
O6-methylguanine-DNA methyltransferase in ovarian malignancy and its correlation with postoperative response to chemotherapy.
O6-Methylguanine-DNA methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics.
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
O6-methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage.
O6-methylguanine-DNA methyltransferase modulates cisplatin-induced DNA double-strand breaks by targeting the homologous recombination pathway in nasopharyngeal carcinoma.
O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.
O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors.
On the quantitative relationship between O6-methylguanine residues in genomic DNA and production of sister-chromatid exchanges, mutations and lethal events in a Mer- human tumor cell line.
Overexpression of DNA methyltransferase 1 (DNMT1) protein in astrocytic tumour and its correlation with O6-methylguanine-DNA methyltransferase (MGMT) expression.
p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors.
Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer.
Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Pediatric Gliosarcoma With and Without Neurofibromatosis Type 1: A Whole-exome Comparison of 2 Patients.
Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer.
Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes.
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer.
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates.
Polar, functionalized guanine-O6 derivatives resistant to repair by O6-alkylguanine-DNA alkyltransferase: implications for the design of DNA-modifying drugs.
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential.
Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET.
Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma.
Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas.
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.
Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression.
Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients.
Promoter methylation of MGMT gene in serum of patients with esophageal squamous cell carcinoma in North East India.
Promoter methylation status of multiple genes in brain metastases of solid tumors.
Properties of the O6-alkylguanine-DNA repair system of mammalian cells.
Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
Protection of mammalian cells against chloroethylating agent toxicity by an O6-benzylguanine-resistant mutant of human O6-alkylguanine-DNA alkyltransferase.
Protein phosphorylation is a regulatory mechanism for O6-alkylguanine-DNA alkyltransferase in human brain tumor cells.
Pyrosequencing assays to study promoter CpG site methylation of the O6-MGMT, hMLH1, p14ARF, p16INK4a, RASSF1A, and APC1A genes.
Quantification of O6-methylguanine-DNA methyltransferase mRNA in human brain tumors.
Quantitation of DNA repair capacities of human tumor cells by estimation of transfer of DNA adducts to repair proteins.
Quantitation of O6-methylguanine-DNA methyltransferase gene messenger RNA in gliomas by means of real-time RT-PCR and clinical response to nitrosoureas.
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Re: S. M. Bronstein et al. Efficient repair of O6-ethylguanine, but not O4-ethylthymine or O2-ethylthymine, is dependent upon O6-alkylguanine-DNA alkyltransferase and nucleotide excision repair activities in human cells. Cancer Res., 52: 2008-2011, 1992.
Reaction of O6-benzylguanine-resistant mutants of human O6-alkylguanine-DNA alkyltransferase with O6-benzylguanine in oligodeoxyribonucleotides.
Receptor tyrosine kinase expression in high-grade gliomas before and after chemoradiotherapy.
Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas.
Recurrent high-grade glioma.
Recurrent Metastasized Parathyroid Carcinoma-Long-Term Remission After Combined Treatments With Surgery, Radiotherapy, Cinacalcet, Zoledronic Acid, and Temozolomide.
Reductive Activity and Mechanism of Hypoxia- Targeted AGT Inhibitors: An Experimental and Theoretical Investigation.
Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling.
Regulation of O6-methylguanine-DNA methyltransferase by methionine in human tumour cells.
Release of 7-alkylguanines from haloethylnitrosourea-treated DNA by E. coli 3-methyladenine-DNA glycosylase II.
Relevance of environmental alkylating agents to repair protein O6-alkylguanine-DNA alkyltransferase: determination of individual and collective repair capacities of O6-methylguanine.
Repression of MLH1 and MGMT genes in colon mucosa adjacent to implanted cancer in athymic mouse.
Resistance of the human O6-alkylguanine-DNA alkyltransferase containing arginine at codon 160 to inactivation by O6-benzylguanine.
Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.
Retroviral transfer of a bacterial alkyltransferase gene (ada) into human bone marrow cells protects against O6-benzylguanine plus 1, 3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity.
Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents.
Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine.
Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents.
Role of postoperative tumor volume in patients with MGMT-unmethylated glioblastoma.
S-alkylthiolation of O6-methylguanine-DNA-methyltransferase (MGMT) to sensitize cancer cells to anticancer therapy.
Salvage therapy with Temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
Sensitization of human colon tumour cell lines to carmustine by depletion of O6-alkylguanine-DNA alkyltransferase.
Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study.
Sequential therapy with dacarbazine and carmustine: a phase I study.
Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors.
Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer.
Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
SNP rs16906252C>T is an expression and methylation quantitative trait locus associated with an increased risk of developing MGMT-methylated colorectal cancer.
Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression.
Specific amino acid sequences required for O6-methylguanine-DNA methyltransferase activity: analyses of three residues at or near the methyl acceptor site.
Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis.
Strategies to Improve the Killing of Tumors Using Temozolomide: Targeting the DNA Repair Protein MGMT.
Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase.
Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature.
Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors: Small Steps Toward Personalized Medicine?
Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas.
Synthesis and antiproliferative activity of 3-(2-chloroethyl)-5-methyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4-(3H)-one.
Synthesis and preliminary biological evaluation of O6-[4-(2-[18F]fluoroethoxymethyl)benzyl]guanine as a novel potential PET probe for the DNA repair protein O6-alkylguanine-DNA alkyltransferase in cancer chemotherapy.
Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.
Temozolomide analog PMX 465 downregulates MGMT expression in HCT116 colorectal carcinoma cells.
Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications.
The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells.
The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status.
The DNA repair protein O6-methylguanine-DNA methyltransferase protects against skin tumor formation induced by antineoplastic chloroethylnitrosourea.
The effect of race on the prognosis of the glioblastoma patient: a brief review.
The effects of X-irradiation, N-ethyl-N-nitrosourea or combined treatment on O6-alkylguanine-DNA alkyltransferase activity in fetal rat brain and liver and the induction of CNS tumours.
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
The Multipotential of Leucine-Rich ?-2 Glycoprotein 1 as a Clinicopathological Biomarker of Glioblastoma.
The prognostic impact of O6-Methylguanine-DNA Methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma.
The promoter methylation and expression of the O6-methylguanine-DNA methyltransferase gene in uterine sarcoma and carcinosarcoma.
The role of mRNA stability and transcription in O6-methylguanine DNA methyltransferase (MGMT) expression in Mer+ human tumor cells.
The role of O-6 methylguanine DNA methyltransferase (MGMT) in drug resistance and strategies for its inhibition.
The specific role of O6-methylguanine-DNA methyltransferase inhibitors in cancer chemotherapy.
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Transfer and expression of human O6-methylguanine-DNA methyltransferase cDNA confers resistance of Mer- HeLa MR cells to 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosoure a.
Transgenic cancer resistant mice carrying the E. coli O6-alkylguanine-DNA alkyltransferase gene, ada.
Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea.
Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
Use of antibodies to human O6-alkylguanine-DNA alkyltransferase to study the content of this protein in cells treated with O6-benzylguanine or N-methyl-N'-nitro-N-nitrosoguanidine.
Variability and regulation of O6-alkylguanine-DNA alkyltransferase.
Wnt/?-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
[Basic principles of diagnosis and treatment of gliomas].
[Clinicopathological diagnosis of gliomas by genotype analysis]
[Effects of dujieqing oral liquid on the promoter methylation of the MGMT gene in middle-and-late stage tumor patients receiving chemotherapy].
[Expression of extraneuronal monoamine transporter gene and DNA repair gene vis-à-vis with antitumor efficacy of SarCNU in human tumor xenografts]
[Gene therapy using anticancer drug-resistance genes]
[Interdisciplinary neuro-oncology: part 1: diagnostics and operative therapy of primary brain tumors].
[Interdisciplinary neuro-oncology: part 2: systemic therapy of primary brain tumors].
[Methylation pattern of DNA repair genes and microsatellite instability in hepatocelluar carcinoma]
[Mutation of human O6-alkylguanine-DNA alkyltransferase confers resistance to O6-benzylguanine]
[O6-methylguanine-DNA-methyltransferase and prediction of cancer chemotherapy]
[Specific curative effects of nitrosourea drugs on tumor cells with Mer--phenotype in Chinese]
[Study on MGMT assay and tumor individual predictable chemotherapy]
[The expression of MGMT in pituitary adenomas and its association with tumour aggressiveness].
[Treatment of glioma with temozolomide]
Neoplasms, Neuroepithelial
Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes.
Neural Tube Defects
MGMT is down-regulated independently of promoter DNA methylation in rats with all-trans retinoic acid-induced spina bifida aperta.
Neuroblastoma
Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.
IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression.
Neuroendocrine Tumors
Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET.
Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).
Neurofibromatosis 1
Inherited predisposition to glioma.
Neurologic Manifestations
Extensive leptomeningeal intracranial and spinal metastases in a patient with a supratentorial glioblastoma multiforme, IDH-wildtype: A case report.
Oligodendroglioma
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?
Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression.
Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Ovarian Neoplasms
Expression of O6-alkylguanine-DNA-alkyltransferase in situ in ovarian and Hodgkin's tumours.
MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer.
Multiple drug resistance parameter expression in ovarian cancer.
Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.
Pancreatic Neoplasms
MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Pancytopenia
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status.
Papillomavirus Infections
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.
Pituitary Neoplasms
Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression.
[The expression of MGMT in pituitary adenomas and its association with tumour aggressiveness].
Pleural Effusion, Malignant
Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer.
Combining ADA, protein and IFN-gamma best allows discrimination between tuberculous and malignant pleural effusion.
Prostatic Neoplasms
The Role of O6-methylguanine-DNA Methyltransferase Polymorphisms in Prostate Cancer Susceptibility: a Meta-Analysis.
Psoriasis
Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States.
Retinoblastoma
Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastoma.
Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues.
Lack of expression of tumor-suppressor genes in human malignant glioma cell lines.
Rhabdomyosarcoma
Cytosine methylation and suppression of O6-methylguanine-DNA methyltransferase expression in human rhabdomyosarcoma cell lines and xenografts.
Identification of nitrosourea-resistant human rhabdomyosarcomas by in situ immunostaining of O6-methylguanine-DNA methyltransferase.
O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea.
O6-methylguanine-DNA methyltransferase activity and promoter methylation status in pediatric rhabdomyosarcoma.
Response of cultured human cell lines from rhabdomyosarcoma xenografts to treatment with chloroethylnitrosoureas.
Rhabdomyosarcoma, Alveolar
Successful treatment of metastatic alveolar rhabdomyosarcoma with MGMT gene promoter methylation by temozolomide-based combination chemotherapy.
Sarcoma
Association between methylation of DNA damage response-related genes and DNA damage in hepatocytes of rats following subchronic exposure to vinyl chloride.
Diffuse leptomeningeal glioneuronal tumor in a Chinese adult: a novel case report and review of literature.
O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcoma.
The promoter methylation and expression of the O6-methylguanine-DNA methyltransferase gene in uterine sarcoma and carcinosarcoma.
Sarcoma, Avian
Expression of human O6-methylguanine-DNA methyltransferase in a DNA excision repair-deficient Chinese hamster ovary cell line and its response to certain alkylating agents.
Expression of human O6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells and restoration of cellular resistance to certain N-nitroso compounds.
Seizures
Analysis of risk factors and clinical sequelae of direct electrical cortical stimulation-induced seizures and afterdischarges in patients undergoing awake mapping.
Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis.
Sepsis
Alterations in the activities of DNA topoisomerase enzymes and O6-methylguanine-DNA-methyltransferase in septic rat liver.
Severe Combined Immunodeficiency
Adenosine deaminase (ADA) deficiency in cells derived from humans with severe combined immunodeficiency is due to an aberration of the ADA protein.
Shock, Septic
Alterations in the activities of DNA topoisomerase enzymes and O6-methylguanine-DNA-methyltransferase in septic rat liver.
Squamous Cell Carcinoma of Head and Neck
Clinical significance of epigenetic silencing and re-expression of O6-methylguanine-DNA methyltransferase using epigenetic agents in laryngeal carcinoma.
Effect of TET1 regulating MGMT on chemotherapy resistance of oral squamous cell carcinoma stem cells.
Loss expression of O6-methylguanine DNA methyltransferase by promoter hypermethylation and its relationship to betel quid chewing in oral squamous cell carcinoma.
O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
Promoter hypermethylation of DNA repair gene MGMT in laryngeal squamous cell carcinoma.
[Promoter hypermethylation of DNA repair gene O6-methylguanine DNA methyltransferase in laryngeal squamous cell carcinoma]
Starvation
Oxygen-dependent inactivation of glutamine phosphoribosylpyrophosphate amidotransferase in stationary-phase cultures of Bacillus subtilis.
Stomach Neoplasms
Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.
Atomic Insight into the Altered O6-Methylguanine-DNA Methyltransferase Protein Architecture in Gastric Cancer.
Biomarkers of individual susceptibility to carcinogens: application for biological monitoring.
BRAF/K-ras mutation, microsatellite instability, and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas.
Evaluation of O6-methylguanine DNA methyltransferase activity in patients with gastric cancer.
Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers.
Teratocarcinoma
Changes in alkylation damage removal during in vitro neuronal differentiation.
Testicular Neoplasms
DNA repair protein O6-methylguanine-DNA methyltransferase in testis and testicular tumors as determined by a novel nonradioactive assay.
Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer.
Thrombocytopenia
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status.
Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity.
Thyroid Cancer, Papillary
Glutathione S-transferase and O6-methylguanine DNA methyl transferase activities in patients with thyroid papillary carcinoma.
Thyroid Neoplasms
Glutathione S-transferase and O6-methylguanine DNA methyl transferase activities in patients with thyroid papillary carcinoma.
Tuberculosis
Adenylylation and catalytic properties of Mycobacterium tuberculosis glutamine synthetase expressed in Escherichia coli versus mycobacteria.
Biochemical and structural studies of the Mycobacterium tuberculosis O6-methylguanine methyltransferase and mutated variants.
Combining ADA, protein and IFN-gamma best allows discrimination between tuberculous and malignant pleural effusion.
Crystal structure of Mycobacterium tuberculosis O6-methylguanine-DNA methyltransferase protein clusters assembled on to damaged DNA.
Urinary Bladder Neoplasms
Exon 3 polymorphisms and haplotypes of O6-methylguanine-DNA methyltransferase and risk of bladder cancer in southern China: a case-control analysis.
O6-alkylguanine-DNA alkyltransferase activity in schistosomiasis-associated human bladder cancer.
O6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines.
Werner Syndrome
Epigenetic deregulation of DNA repair and its potential for therapy.
Xeroderma Pigmentosum
Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.
Evidence for the excision repair of O6-n-butyldeoxyguanosine in human cells.
Toxicity, mutagenicity, and mutational spectra of N-ethyl-N-nitrosourea in human cell lines with different DNA repair phenotypes.